» Articles » PMID: 21969503

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

Abstract

Purpose: Recent increases in incidence and survival of oropharyngeal cancers in the United States have been attributed to human papillomavirus (HPV) infection, but empirical evidence is lacking.

Patients And Methods: HPV status was determined for all 271 oropharyngeal cancers (1984-2004) collected by the three population-based cancer registries in the Surveillance, Epidemiology, and End Results (SEER) Residual Tissue Repositories Program by using polymerase chain reaction and genotyping (Inno-LiPA), HPV16 viral load, and HPV16 mRNA expression. Trends in HPV prevalence across four calendar periods were estimated by using logistic regression. Observed HPV prevalence was reweighted to all oropharyngeal cancers within the cancer registries to account for nonrandom selection and to calculate incidence trends. Survival of HPV-positive and HPV-negative patients was compared by using Kaplan-Meier and multivariable Cox regression analyses.

Results: HPV prevalence in oropharyngeal cancers significantly increased over calendar time regardless of HPV detection assay (P trend < .05). For example, HPV prevalence by Inno-LiPA increased from 16.3% during 1984 to 1989 to 71.7% during 2000 to 2004. Median survival was significantly longer for HPV-positive than for HPV-negative patients (131 v 20 months; log-rank P < .001; adjusted hazard ratio, 0.31; 95% CI, 0.21 to 0.46). Survival significantly increased across calendar periods for HPV-positive (P = .003) but not for HPV-negative patients (P = .18). Population-level incidence of HPV-positive oropharyngeal cancers increased by 225% (95% CI, 208% to 242%) from 1988 to 2004 (from 0.8 per 100,000 to 2.6 per 100,000), and incidence for HPV-negative cancers declined by 50% (95% CI, 47% to 53%; from 2.0 per 100,000 to 1.0 per 100,000). If recent incidence trends continue, the annual number of HPV-positive oropharyngeal cancers is expected to surpass the annual number of cervical cancers by the year 2020.

Conclusion: Increases in the population-level incidence and survival of oropharyngeal cancers in the United States since 1984 are caused by HPV infection.

Citing Articles

Virus-mediated immunosuppression in head and neck cancer.

Miyauchi S, Roy S, Boutros N, Sharabi A Oncogene. 2025; .

PMID: 40074885 DOI: 10.1038/s41388-025-03295-2.


VOYAGER: an international consortium investigating the role of human papilloma virus and genetics in oral and oropharyngeal cancer risk and survival.

Gormley M, Adhikari A, Dudding T, Pring M, Hurley K, Macfarlane G medRxiv. 2025; .

PMID: 40034767 PMC: 11875266. DOI: 10.1101/2025.02.17.25322399.


Role of the AIM2 Inflammasome in Cancer: Potential Therapeutic Strategies.

Colarusso C, Terlizzi M, Di Caprio S, Falanga A, DAndria E, dEmmanuele di Villa Bianca R Biomedicines. 2025; 13(2).

PMID: 40002808 PMC: 11852973. DOI: 10.3390/biomedicines13020395.


Development and Validation of an Assay to Quantify Plasma Circulating Tumor Human Papillomavirus DNA for 13 High-Risk Types that Cause 98% of HPV-Positive Cancers.

Wotman M, Xiao W, Du R, Jiang B, Akagi K, Liu S Head Neck Pathol. 2025; 19(1):25.

PMID: 39998590 PMC: 11861489. DOI: 10.1007/s12105-025-01752-8.


Characterization of the Genomic Landscape in HPV-positive Cervical and Head and Neck Squamous Cell Carcinomas by Whole Genome Next Generation Sequencing.

Ren J, Ma N, Seckar T, Bassa S, Zetola N, Grover S Cancer Genomics Proteomics. 2025; 22(2):188-207.

PMID: 39993810 PMC: 11880920. DOI: 10.21873/cgp.20496.


References
1.
Kim J . Focus on research: weighing the benefits and costs of HPV vaccination of young men. N Engl J Med. 2011; 364(5):393-5. DOI: 10.1056/NEJMp1012246. View

2.
Peto J, Decarli A, La Vecchia C, Levi F, Negri E . The European mesothelioma epidemic. Br J Cancer. 1999; 79(3-4):666-72. PMC: 2362439. DOI: 10.1038/sj.bjc.6690105. View

3.
Fleming D, McQuillan G, Johnson R, Nahmias A, Aral S, Lee F . Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 1997; 337(16):1105-11. DOI: 10.1056/NEJM199710163371601. View

4.
Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren L, Joneberg J . Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006; 119(11):2620-3. DOI: 10.1002/ijc.22177. View

5.
Chaturvedi A, Engels E, Anderson W, Gillison M . Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008; 26(4):612-9. DOI: 10.1200/JCO.2007.14.1713. View